WALTHAM, Mass.--(BUSINESS WIRE)--NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it met its planned marketing launch date for NC-stat®|DPNCheck™, which is a fast, accurate, and quantitative test for the evaluation of systemic neuropathies such as diabetic peripheral neuropathy (DPN). The launch occurred at the American Diabetes Association 71st Scientific Sessions in San Diego, CA on June 24-28, 2011. NC-stat DPNCheck measures sural nerve conduction velocity and response amplitude, which are standard biomarkers for diabetic peripheral neuropathy. The device is a modified version of the widely used NC-stat® device which has been shown to accurately detect DPN.
